Stock 603739 QINGDAO VLAND BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Qingdao Vland Biotech INC.

Equities

603739

CNE100003GX8

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
19.4 CNY -4.90% Intraday chart for Qingdao Vland Biotech INC. +39.87% +27.46%
05-07 China stocks edge down; HK shares fall after 10-day winning streak RE
04-25 Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
China stocks edge down; HK shares fall after 10-day winning streak
RE
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Qingdao Vland Biotech Forms Chinese JV With Germany’s Evonik
MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Qingdao Vland Biotech INC. completed the acquisition of 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders.
CI
Qingdao Vland Biotech Acquires 51% of Runbot Biotechnology for 91.8 Million Yuan
MT
Qingdao Vland Biotech INC. signed a share transfer agreement to acquire a 51% stake in Qingdao RBT Biotechnology Co., Ltd. from Qingdao Jurun Management Consulting Partnership (Limited Partnership), Qingdao Gerunpu Management Consulting Partnership (Limited Partnership) and other individual shareholders for CNY 91.8 million.
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Qingdao Vland Biotech's Joint Venture to Invest Up to 400 Million Yuan for Probiotic Food Plant
MT
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Qingdao Vland Biotech INC. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Weifang Weizhilan Biological Technology Co., Ltd. announced that it expects to receive CNY 182.888 million in funding from Qingdao Vland Biotech INC., Archer Daniels Midland Singapore Pte Ltd.
CI
Archer Daniels Midland : to Create Human Probiotics Joint Venture With Qingdao Vland Biotech Group
MT
Qingdao Vland Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603739 Stock
  4. News Qingdao Vland Biotech INC.